Study Identifies Prognostic Factors from Anti-PD-1 Therapy Use in Advanced MelanomaSeptember 15, 2020 • By Support
Source: cancernetwork, September 2020
Prognostic factors in advanced melanoma were identified for patients who experienced disease progression while receiving anti-PD-1, including lactate dehydrogenase, stage of disease, site of disease progression, tumor size, and mutation status, according to a study published in Cancer.
“The current study identified multiple prognostic factors in patients with advanced melanoma who developed disease progression while receiving anti-PD-1,” wrote the researchers. “Furthermore, the current study has provided additional benchmarks for the activity of existing therapies in the post-progression setting, and identified a cohort of long-term, post-progression survivors.”
A total of 247 patients experienced disease progression out of the 383 patients included in the study cohort. Median survival after disease progression was 6.8 months, with no difference in survival found after disease progression based on primary tumor subtype, receipt of prior therapy, or therapy type.
[button link="https://www.cancernetwork.com/view/study-identifies-prognostic-factors-from-anti-pd-1-therapy-use-in-advanced-melanoma" window="yes"]READ THE ORIGINAL FULL ARTICLE[/button]